Neuroblastoma in Adults vs Children: Key Differences

Although cancer is often thought of as a condition of older people, certain cancers are seen mainly in very young patients. Neuroblastoma, a cancer of neural tissue, represents roughly six per cent of all cancers in children and is one of the more typical solid tumours in children. However, when this condition occurs in grown-up patients, it acts in a completely different way, which brings about particular problems in diagnosis and care. 

The patient’s age at the point of developing the illness fundamentally changes how it acts and what it is like. Children often have very aggressive tumours which, strangely, respond to treatment better; adults, however, tend to have disease that grows more slowly, but is more difficult to treat. Knowing about these differences relating to age helps families and patients to deal with what can seem to be a very difficult diagnosis. 

Biological Differences Related to Age 

Tumours in babies come from immature nerve cells which still have the power to become mature or disappear on their own. This flexibility in development explains why some babies with widespread disease do not need strong treatment. Their immune systems appear to be better at recognising and destroying cancer cells naturally. The tumours in very young patients frequently have genetic features which are linked to good results. 

Neuroblastoma in adults has very different biological features which make treatment more difficult. Adult tumours develop from cells which have lost their developmental plasticity and their power to change into normal tissue. These mature, malignant cells are more resistant to standard chemotherapy treatments than those in children. The genetic structure of the illness in adults shows different patterns of mutation which are rarely seen in childhood cases. 

Patterns of Location Across Age Groups 

Tumours in children usually start in the adrenal glands or along the sympathetic chain in the abdomen. This pattern of distribution is due to the paths followed by neural crest cells during the development of the foetus. About 40 per cent of cases in children begin in the adrenal medulla, and another 25 per cent develop in sympathetic ganglia in the abdomen. The chest and neck are the sites of most of the remaining cases in childhood. 

In adults, the illness tends to prefer different anatomical sites, in particular peripheral sympathetic ganglia. Tumours which start in the pelvis, mediastinum or retroperitoneum are seen more often in adult patients. This different pattern of distribution makes early detection more difficult, as symptoms depend very much on where the tumour is. The anatomical differences also affect surgical methods and the planning of radiation fields. 

How Symptoms Show Themselves Varies 

Young children often show abdominal swelling which parents notice during normal care such as bathing or dressing. These visible growths cause medical examination relatively quickly, although the tumours may already be quite big. Fever, pain in the bones, and limping occur when the disease spreads to the bones. Sometimes babies develop bluish skin growths which show that the disease has spread. 

Adults usually report unclear symptoms which continue for months before diagnosis. Long-lasting back pain, tiredness, or non-specific stomach discomfort rarely cause an immediate thought of cancer. This delay in diagnosis allows neuroblastoma cancer to go on without being noticed for long periods. Loss of weight and night sweats may eventually cause investigation, but these symptoms are the same as many harmless conditions. 

Treatment Methods Differ 

Treatment in children uses surgery, neuroblastoma chemotherapy, radiation, and sometimes stem cell transplant, based on how much risk there is. Drug treatments include platinum compounds, alkylating agents, and topoisomerase inhibitors, given in strong cycles. Children are able to take these poisonous treatments better than adults, because of their greater physical strength. Patients at high risk receive chemotherapy which destroys the bone marrow, followed by rescue using their own stem cells. 

Treatment plans for adults must take into account the lower ability to take strong chemotherapy and the higher rates of problems. Lower doses of drugs become necessary to stop damage to organs, which may reduce the chances of a cure. Surgical removal plays a more important part when it is possible, given the limits of chemotherapy. Centres like Fortis Healthcare, Gurgaon offer specialised programmes which balance the strength of treatment against the particular weaknesses of adult patients. 

Genetic Factors Play Different Roles 

MYCN amplification happens in about 20 per cent of cases in children and strongly shows that the behaviour will be aggressive. This genetic alteration causes cells to multiply without control and become unresponsive to usual treatments. Young patients whose tumours show MYCN amplification – too much of the MYCN gene – need the strongest, most varied treatment we can give. Chromosome problems, such as loss of 1p and 11q, also seriously affect a child’s chance of getting better. 

Adult tumours display different molecular characteristics and, in general, have lower levels of MYCN amplification. ALK mutations are seen more often in adult cases than in children. These genetic differences imply that different processes cause the tumours to develop in the two age groups. When they are available, knowing the molecular features helps to select treatments which are aimed at specific faults. 

Expectations for Outcomes Change With Age 

When all risk levels are combined, over 80% of children with neuroblastoma survive. Paediatric patients at low risk have more than 95% cure rates, needing only a little treatment. Even children at high risk reach around 50 to 60% survival with strong treatment. Babies with Stage MS disease very often get better on their own, without the need for chemotherapy. 

Neuroblastoma in adults has a considerably poorer outlook, despite seeming less aggressive at first. Five-year survival is between 30 and 50% depending on how advanced the disease is and how well it responds to treatment. The illness acts more as a slowly-developing cancer which eventually becomes immune to treatment. Long-lasting remission is possible, but needs continuous, varied treatment. 

How Tumours Behave is Different 

Childhood neuroblastoma causes quick cell division and fast development of symptoms – in weeks or months. Tumours are able to double in size in short times, making urgent clinical issues. This forceful growth, strangely, shows a biological lack of maturity which makes the cells sensitive to chemotherapy. The quick multiplication also causes high metabolic activity that is seen on functional scans. 

Adult tumours grow much more slowly, sometimes needing years to make noticeable symptoms. This slow behaviour suggests a different control of the cell cycle than in children’s disease. Slower growth reduces the effectiveness of chemotherapy, because drugs work best on cells which are dividing. The long period of the illness makes it difficult to judge outcomes, as relapses can happen many years after treatment. 

Managing Treatment Poisoning 

Children generally get over intensive neuroblastoma chemotherapy more quickly, because of strong organ function. Their bone marrow recovers rapidly after myelosuppression – suppression of bone marrow activity – which shortens the time of infection risk. Nutritional repair happens well once sickness from treatment goes away. Long-term observation deals with possible late effects on growth, fertility and organ function. 

Adults have longer recovery times and more treatment-related problems. Kidney damage from platinum drugs happens more often in older patients. Hearing loss, nerve damage to the limbs and heart problems build up with each treatment course. Needs for supportive care rise greatly, sometimes needing reductions in dose which weaken effectiveness. 

Different Patterns of Recurrence 

Paediatric relapses usually occur within two years of finishing treatment, if they happen at all. Bone marrow and bone are the most common places for the disease to come back. Early relapse means the illness is resistant, requiring experimental rescue treatments. Late relapses, after a long time in remission, can respond to normal re-induction therapy. 

Adult recurrences follow less certain patterns, sometimes appearing many years after what seemed a cure. The slow growth of the tumour lets microscopic illness stay hidden for long periods. Adult neuroblastoma cancer which comes back rarely responds for long to more cycles of chemotherapy. New treatments which aim at specific faults and immunotherapy give the best hope for lasting control of the illness. 

Different Surveillance Strategies 

Children have intensive observation with frequent scans and laboratory tests during the first two years after treatment. How often imaging is done is gradually reduced as time from diagnosis gets longer. Catecholamine markers give early warning of recurrence before symptoms appear. Long-term follow-up deals with late effects from radiation and chemotherapy. 

Adults need long-lasting observation, given unpredictable relapses and a longer course of the illness. Yearly imaging may go on for ever, rather than being spaced out over time. Assessment of hormone production becomes important, as many adults develop hormone shortages from treatment. Monitoring of quality of life deals with chronic poisonings which build up with age.